Introduction
============

Brucellosis is a contagious disease affecting humans and domestic animals \[[@B22]\]. Due to its significant socioeconomic impact in terms of decreased animal productivity, including decreased milk production, abortion, and infertility, brucellosis is considered an important disease \[[@B17][@B26]\]. *Brucella*, the causative agent, binds to distinct phagocytic receptors resulting in zipper-like phagocytosis or phagocytosis through lipid raft microdomains. It is exposed to a harsh environment once inside a host cell but develops multiple strategies to evade the host\'s immune response mechanisms, resulting in successful persistent infection and replication \[[@B1][@B20]\]. The mitogen-activated protein kinase (MAPK) cascade is important in the phagocytosis of bacteria via professional phagocytes and remodeling of the actin cytoskeleton \[[@B12]\].

Control programs for animal brucellosis are generally based on vaccination with live attenuated *Brucella abortus* S19 in cattle and *Brucella melitensis* in sheep and goats; however, these vaccines may cause abortion, premature birth, and decreased milk yield, hence their use has been eliminated for use in cattle in Korea \[[@B7][@B26]\]. The use of antibiotics does not seem to have a significant role in brucellosis control programs, particularly in productive animals, due to economic, epidemiological, and public health factors \[[@B16]\]. Furthermore, treatment for brucellosis is complicated due to emerging treatment resistance that leads to high treatment failure or relapse rates \[[@B17]\]. Therefore, it is necessary to find alternative control options that are safe and effective in the treatment of brucellosis.

Tannins are natural products commonly found in almost every plant part and are known for their antimicrobial properties \[[@B24]\]. A specific type of tannin, namely tannic acid (TA), has been reported to inhibit the growth of *Aeromonas hydrophila*, *Aeromonas sobria*, *Escherichia coli*, *Klebsiella pneumonia*, *Listeria monocytogenes*, *Staphylococcus aureus*, *Salmonella* Typhimurium, *Helicobacter pylori*, and *Cytophaga columnaris* \[[@B9]\]. The reported possible mechanism for such inhibition mainly involves the bacterial cell wall, resulting in lysis of complexes within cell wall proteins, membrane disruption metal ion complexation, and binding to adhesions \[[@B18]\]. In our previous study, tannin-derived components of *galla rhois* (GR), collectively TA, methyl gallate (MG), and gallic acid, were reported to have a bactericidal effect against *B. abortus* infection when applied as a GR ethanol extract and to have an inhibitory effect on bacterial proliferation in mouse spleen \[[@B11]\]. In addition, we have also demonstrated therapeutic effects of MG against *Brucella* infection; effects transpiring via induction of cytokine production \[[@B21]\]. Consequently, in this study, we investigated the therapeutic effects of TA, another GR component, on the splenic proliferation of *B. abortus* and the host immune response in a mouse model.

Materials and Methods
=====================

Tannic acid preparation
-----------------------

TA (Sigma-Aldrich, USA) was dissolved in sterile phosphate-buffered saline solution (PBS, pH 7.4) (100 mg/mL) and sterilized via membrane filtration (0.45 µm membranes, Minisart; Sartorius Stedim Biotech, Germany).

Bacterial strains
-----------------

The *B. abortus* 544 (ATCC 23448) strain was obtained from the Laboratory of Bacteriology Division in Animal and Plant Quarantine Agency, Korea and cultivated in Brucella broth (Becton Dickinson, USA) at 37℃ with aeration. Routine cultivation was carried out in Brucella broth or agar (1.5%).

Cell culture
------------

Murine RAW 264.7 cells (American Type Culture Collection, USA) were grown at 37℃ with 5% CO~2~ atmosphere as previously described \[[@B20]\] and were seeded in tissue culture plates at a concentration of 1 × 10^5^ cells per well. Culture medium was changed to fresh medium without antibiotics prior to infection.

Cytotoxicity assay
------------------

The cells were incubated with different concentrations of TA (0, 40, 80, 100, and 200 µg/mL) in a 96-well cell culture plate. After 48 h of incubation, cell viability was assessed by using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

F-actin staining and FACS analysis
----------------------------------

For F-actin staining, pre-treated macrophages were prepared in 12-well plates with 18-mm diameter glass coverslips and were infected with fluorescein isothiocyanate (FITC)-conjugated *B. abortus* as previously described \[[@B20]\]. Macrophages were viewed under a laser scanning confocal microscope (Olympus FV1000; Olympus, Japan) and images were processed by using FV10-ASW Viewer software (ver. 3.1; Olympus).

For fluorescence-activated cell sorting (FACS) analysis, cells in six-well plates were harvested after pre-treatment and infection as described above. Lysophosphatidylcholine (20 µg/mL) containing tetramethylrhodamine isothiocyanate (TRITC)-phalloidin (1 µM) was used to permeabilize and stain the infected cells (both purchased from Sigma-Aldrich) followed by incubation for 30 min at 22℃. After final washing, the F-actin content was quantified by using a FACSVerse flow cytometer (BD Biosciences, USA).

Western blotting
----------------

Pre-treatment and infection of macrophages was undertaken as previously described \[[@B20]\]. Lysis of cells, measurement of protein concentration, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and western blotting were performed as previously described \[[@B21]\].

Protective effect and immune response analysis
----------------------------------------------

Specific-pathogen-free female ICR mice (six-to eight-week-old mice) were maintained at 23℃ ± 1℃ with a 12 h light/dark cycle and free access to food and water and acclimatized for at least one week prior to use in experiments. The mice were randomly grouped into groups of 4 to 5 mice each; two non-infected groups were orally given PBS (negative control) or TA (80 µg/mL) and two infected groups were orally given PBS (positive control) or TA (80 µg/mL). Infection was performed intraperitoneally with an injection of 2 × 10^4^ colony-forming units (CFUs) of *B. abortus*. Oral treatment was given three days prior to infection and continued until 14 days post-infection. At three days post-infection, serum samples from the tail vein were collected, and, at 14 days post-infection, the mice were sacrificed. Blood was then collected from the hearts, and spleens were removed and weighed. Spleens of infected mice were homogenized, serially diluted in PBS, and plated on Brucella agar as previously described \[[@B11]\]. The agar plates were incubated at 37℃ for three days and the number of CFUs for each spleen was counted. All of the procedures were approved by the Animal Ethical Committee of Gyeongsang National University (approval No. GNU-120423-M0012).

The levels of interleukin (IL)-12p70, tumor necrosis factor (TNF), interferon-γ (IFN-γ), monocyte chemoattractant protein-1 (MCP-1), IL-10, and IL-6 in the serum samples were analyzed as previously described \[[@B13]\] by using a mouse inflammation cytometric bead array kit (BD Biosciences) according to the manufacturer\'s instructions. Cytokines were measured by using a FACSVerse flow cytometer (BD Biosciences). Briefly, 50 µL serum samples were added to Falcon tubes with an equal volume of mixed capture beads. Fifty microliters of Mouse Inflammation PE Detection Reagent were added and the mixture incubated for 2 h at room temperature in the dark. One milliliter of wash buffer was then added and the mixture centrifuged at 200 × g for 5 min. The supernatant was carefully removed and 300 µL of wash buffer was added to resuspend the bead pellet. BD CellQuest software was used for data acquisition, and the data were analyzed by Becton, Dickinson and Company (USA).

Statistical analysis
--------------------

The results for each experiment are expressed as means ± SD. Statistical analysis was performed in GraphPad InStat software (ver. 3; GraphPad Software, USA) with Student\'s *t*-test or one-way analysis of variance (ANOVA) applied for statistical comparisons between groups.

Results
=======

Effects on murine macrophage viability
--------------------------------------

The cytotoxicity of TA was evaluated by incubating RAW 264.7 cells with different concentrations of TA (0, 40, 80, 100, and 200 µg/mL) for 48 h. Cell viability remained at 100% with no change in optical density (OD) values at or below concentrations of 80 µg/mL. The highest concentration (80 µg/mL) at which the OD values did not change was used in subsequent experiments.

Effects on F-actin polymerization and MAPK phosphorylation
----------------------------------------------------------

Under fluorescence microscopy, attenuated F-actin polymerization was observed in infected TA-treated cells (panel A in [Fig. 1](#F1){ref-type="fig"}) and was confirmed through the use of a FACS assay, which revealed a 1.11-fold reduction from that of the positive control (panel B in [Fig. 1](#F1){ref-type="fig"}). No significant difference in F-actin fluorescence was observed between the non-infected groups. In our previous study (unpublished data), TA effectively reduced invasion of *B. abortus* in RAW 264.7 cells, and the results in this study indicate that this inhibition could be due to attenuation of F-actin polymerization, which is essential for the uptake of microbial pathogens by phagocytes. In addition, treatment of cells with TA suppressed phosphorylation of ERK 1/2 and p38α in TA-treated cells by 3.33- and 1.80-fold, respectively, at 30 min post-infection as compared to the positive controls ([Fig. 2](#F2){ref-type="fig"}), indicating a negative effect on bacterial invasion into macrophages.

Effects on bacterial proliferation in mice
------------------------------------------

The *in vitro* inhibitory effects of TA were further confirmed by *in vivo* TA treatment of a mouse model. In the non-infected groups, the total weights of spleen collected from TA-treated mice were not significantly different from those of the control group. Although slightly lower, the infected TA-treated mice showed no statistically significant difference in total weights of the spleen when compared with the positive control group ([Fig. 3](#F3){ref-type="fig"}). However, the average number of CFUs in the spleens of TA-treated mice was significantly reduced (1.48-fold, *p* \< 0.05) from that of the positive control ([Fig. 4](#F4){ref-type="fig"}). These results indicated that TA treatment in mice did not effectively reduce inflammation of the spleens, but it did successfully reduce the proliferation of *B. abortus* in spleen.

Effects on immune response in mice
----------------------------------

In the non-infected groups and compared to the control group, the TA-treated mice showed elevated levels of IFN-γ (2.83-fold, *p* \< 0.05), MCP-1 (3.80-fold, *p* \< 0.001) and IL-10 (6.36-fold, *p* \< 0.01) at 3 days post-infection, and further increases in IFN-γ (9.05-fold, *p* \< 0.001) and MCP-1 (2.86-fold, *p* \< 0.05) were observed at 14 days post-infection. In the infected groups, compared to the control group, the TA-treated mice displayed an elevated level of IFN-γ (2.50-fold, *p* \< 0.05) at 3 days post-infection, which was observed to continue to increase at 14 days post-infection (3.25-fold, *p* \< 0.05) in concert with an elevated level of TNF (2.22-fold, *p* \< 0.05) ([Fig. 5](#F5){ref-type="fig"}). Taken together, these findings indicated that TA treatment aids in the enhancement of cytokine release in mice, particularly in those cytokines involved in the cellular-mediated immune response.

Discussion
==========

Brucellosis is considered an emerging infectious disease in many areas of the world with an estimate of 500,000 new cases every year in humans worldwide \[[@B23]\]. No current validated vaccine is available for humans, and the control programs for animal brucellosis are based on vaccination, which has several disadvantages. Moreover, the use of antibiotics for brucellosis treatment is controversial due to the emergence of antibiotic resistance, which leads to treatment failure and relapse. In our previous study (unpublished data), TA was shown to directly inhibit the growth of *B. abortus* in a concentration-dependent manner, as well, TA affected the pathogen\'s internalization into RAW 264.7 cells. The results of this study suggest that the potential of TA to inhibit *B. abortus* invasion is contributed through its inhibitory action on F-actin polymerization and MAPKs phosphorylation (ERK 1/2 and p38α), which are essential for phagocytic uptake of microbes \[[@B12]\]. This is similar to the results of a study performed on cell line HSC-2, established from a human oral squamous cell carcinoma, in which pre-treatment of these cells with TA inhibited the MAPK signaling pathways \[[@B8]\]. Since adhesion is one of the initial stages of the infectious process, TA could be used as an anti-adhesion agent to control *B. abortus* infection and probably other intracellular pathogens.

*Brucella* is a stealthy pathogen with no classical toxins and its intracellular lifestyle limits its exposure to the host\'s innate and adaptive immune responses, protects from the effects of antibiotics, and eventually leads to its pathologic features \[[@B5][@B19]\]. The T helper cell type 1 (Th1) cellular immune response is important for the clearance of *Brucella*, which mainly resides in macrophages, but the effectiveness of the Th2 humoral immune response remains unclear \[[@B5][@B14]\]. These two subclasses of effector helper T cells can be distinguished by examining the cytokines they secrete; cytokines are key factors in protection against brucellosis, mediating and directing the immune response \[[@B3][@B5][@B10]\]. In this study, the cytokine content in serum samples was analyzed as that content was reflective of the infection status of splenic cells \[[@B4]\]. In the non-infected groups, TA-treated mice displayed showed increased production of IFN-γ, MCP-1 and IL-10 at 3 days post-infection. cytokines IFN-γ and MCP-1 were observed to increase until 14 days post-infection, but the IL-10 level did not increase. IFN-γ activates macrophages and is involved in the control of murine brucellosis. MCP-1 regulates the migration and infiltration of monocytes and lymphocytes and has been implicated in host immunity to *Brucella*, while IL-10 aids in preventing further tissue damage \[[@B5][@B6][@B15][@B25]\]. Our cytokine analysis suggests that TA could be used as an immunostimulator or an adjuvant. A previous study reported that TA, in addition to β-lactam antibiotics, can be a useful adjuvant agent for *S. aureus* skin infections \[[@B2]\]. In addition, TA can be a potential adjuvant to improve immune response to co-administered antigens in a vaccine formulation. In *Brucella*-infected groups, increases in IFN-γ levels were observed at both 3 and 14 days post-infection in TA-treated mice. On the other hand, TNF was observed to increase significantly only at 14 days post-infection. *Brucella suis* has been reported to inhibit TNF production in human macrophages, suggestive of the pathogen\'s strategy for intracellular survival \[[@B10]\]. The TNF cytokine maximizes the phagocytic activity of macrophages and is crucial in destroying live *Brucella* within macrophages \[[@B15]\].

TA treatment in mice did not reduce inflammation of the spleens, but it did significantly reduce proliferation of *B. abortus* in these organs. TA has been reported to inhibit the growth of several bacterial pathogens as well as the HIV and influenza viruses. In our unpublished data, TA was observed to directly inhibit the growth of *B. abortus*. Taken together, TA treatment in mice successfully controls *B. abortus* infection in mice, and such control is attributed to the production of important cytokines, particularly those involved in the Th1 cellular immune response, and probably to its bactericidal effect.

In conclusion, the oral treatment of TA in mice can lead to induction of cytokine production and inhibition of *Brucella* proliferation in their spleens. The results of this study highlight the potential of using TA as a therapeutic agent for the control and prevention of animal brucellosis.
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![Effect of tannic acid (TA) on F-actin polymerization in RAW 264.7 cells. (A) The stained cells were viewed under a laser scanning confocal microscope. (B) F-actin content was quantified using a flow cytometer. The values expressed are means ± SD for each group. A statistically significant difference from the control group is indicated by an asterisk (^\*^*p* \< 0.05). DIC, differential interference contrast; *B. abortus*, *Brucella abortus*.](jvs-19-51-g001){#F1}

![Effect of tannic acid (TA) on mitogen-activated protein kinase (MAPK) phosphorylation in RAW 264.7 cells. Cells were pre-treated with TA or PBS. The cells were then infected with *Brucella abortus* and the cell lysates collected. Immunoblot analysis of total RAW 264.7 cell lysates was assessed by using phospho-specific ERK1/2, JNK, and p38α antibodies.](jvs-19-51-g002){#F2}

![Total weight of spleens of mice orally treated with tannic acid (TA) or PBS. Mice were orally given TA or PBS from 3 days prior to infection to 14 days post-infection. The mice were then sacrificed, the spleens harvested and weighed. A statistically significant difference from the control group is indicated by an asterisk (^\*^*p* \< 0.05).](jvs-19-51-g003){#F3}

![Proliferation of *Brucella abortus* in spleens of tannic acid (TA)-treated mice or PBS-treated mice. Mice were orally given TA or PBS from 3 days prior to infection to 14 days post-infection. At 14 days post-infection, mice were sacrificed, and the spleens homogenized and serially diluted in PBS. The number of colony-forming units (CFUs) was counted to assess bacterial proliferation in each spleen. A statistically significant difference from the control group is indicated by an asterisk (^\*\*^*p* \< 0.01).](jvs-19-51-g004){#F4}

![Immune response analysis of tannic acid (TA)-treated mice or PBS-treated mice against *Brucella abortus* infection in mice. Mice were orally given TA or PBS from 3 days prior to infection to 14 days post-infection. At 3 days post-infection, serum samples were collected via tail vein in each animal. At 14 days post-infection, mice were sacrificed, and blood was collected from the heart. Serum samples were analyzed for cytokine release by using a flow cytometer. A statistically significant difference from the control group is indicated by asterisks (^\*^*p* \< 0.05; ^\*\*^*p* \< 0.01; ^\*\*\*^*p* \< 0.001). IL, interleukin; MCP-1, monocyte chemoattractant protein-1; TNF, tumor necrosis factor; IFN, interferon.](jvs-19-51-g005){#F5}
